Premium
High‐risk stage II colon cancer after curative resection
Author(s) -
Sato Harunobu,
Maeda Koutarou,
Sugihara Kenichi,
Mochizuki Hidetaka,
Kotake Kenjiro,
Teramoto Tetsuo,
Kameoka Shingo,
Saito Yukio,
Takahashi Keiichi,
Hirai Takashi,
Ohue Masayuki,
Shirouzu Kazuo,
Sakai Yoshiharu,
Watanabe Toshiaki,
Hirata Koichi,
Hatakeyama Katsuyoshi
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21914
Subject(s) - medicine , colorectal cancer , stage (stratigraphy) , ileus , lymph , surgery , cancer , gastroenterology , oncology , pathology , paleontology , biology
Objectives This study was designed to clarify which attributes of stage II colon cancer are associated with tumor recurrence and survival after curative resection, and the effects of adjuvant chemotherapy (ACT). Methods We retrospectively reviewed outcomes and clinicopathological characteristics of 1476 patients with stage II colon cancer who underwent curative resection. Results Of 1476 patients, 204 (13.8%) developed recurrence. Macroscopic type, serum CA19‐9 levels, venous invasion, emergency operation, and postoperative ileus were independently associated with overall recurrence. Carbohydrate antigen (CA)19‐9 levels, the number of dissected lymph nodes (LN), sex, age, ACT, emergency operation, venous invasion, and macroscopic type were independently associated with poor prognosis. Prognosis was significantly better in patients who received ACT than in those who did not. Among patients with extensive venous invasion, those with fewer than 13 dissected LNs, male patients, and patients >50 years old, the prognosis was significantly better in patients who received ACT than in those who did not. Conclusions ACT for stage II colon cancer is recommended to improve the prognosis of patients with extensive venous invasion, patients with fewer than 13 dissected LNs, patients >50 years old, and male patients, particularly patients with more than two of these risk factors. J. Surg. Oncol. 2011;104:45–52. © 2011 Wiley‐Liss, Inc.